Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others), By Application (Neurology, Hematology, Oncology, Immunology, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 26.81 Billion
CAGR (2026-2031)	6.45%
Fastest Growing Segment	Albumin
Largest Market	North America
Market Size (2031)	USD 39.01 Billion

Market Overview

The Global Plasma Fractionation Market is projected to grow from USD 26.81 Billion in 2025 to USD 39.01 Billion by 2031 at a 6.45% CAGR. Plasma fractionation is the intricate process of separating human blood plasma into its distinct therapeutic protein components, including albumin, immunoglobulins, and coagulation factors. The market's expansion is fundamentally driven by the escalating prevalence of immunological disorders, neurological conditions, and hemophilia, alongside a growing geriatric population requiring advanced plasma-derived therapies. Furthermore, increasing awareness and improved diagnostic capabilities for rare diseases significantly contribute to the demand for these essential medicinal products.

According to the National Blood Centre, in 2025, 919.7 tonnes of plasma were collected in Italy, indicating a sustained increase in raw material supply. Despite this, a significant challenge impeding global market growth is the substantial cost associated with the overall plasma collection and fractionation process. This elevated expense directly impacts the accessibility and affordability of plasma-derived products worldwide, presenting a considerable barrier to broader market penetration.

Key Market Drivers

The rising demand for immunoglobulins across various therapeutic areas represents a pivotal driving force for the global plasma fractionation market. Immunoglobulins are critical in treating a spectrum of conditions, including primary immunodeficiencies, autoimmune disorders, and certain neurological diseases. This sustained demand is fueled by improved diagnostic capabilities leading to earlier identification of these conditions, along with an expanding treatment landscape that increasingly recognizes the efficacy of immunoglobulin therapies. For instance, according to CSL's 2025 Annual Report, published in August 2025, CSL Behring's immunoglobulin revenue reached $6.064 billion in 2025, demonstrating a notable increase from the previous year. This growth underscores the essential role these plasma-derived products play in addressing significant unmet medical needs globally.

Another significant driver is the continuous expansion of plasma collection infrastructure, which is fundamental to ensuring a steady and increasing supply of raw material for fractionation. The development of new collection centers and strategic investments in existing facilities directly impacts the availability of plasma, thereby enabling greater production of essential plasma-derived medicinal products. For example, according to Fierce Pharma, September 2025, Kedrion Biopharma announced plans to invest over $260 million towards expanding its U.S. network with more than 40 new plasma collection centers. This commitment reflects the industry’s proactive approach to bolstering supply. Furthermore, the overall market continues to attract substantial investment, as evidenced by Octapharma's 2025 Annual Report, published in February 2026, where the company reported investing over €440 million in 2025 to strengthen its portfolio and support future growth. These efforts collectively contribute to the market's capacity to meet global patient demands.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with the overall plasma collection and fractionation process represents a significant impediment to the growth of the Global Plasma Fractionation Market. This elevated expense directly influences the final pricing of plasma-derived medicinal products. Consequently, the accessibility and affordability of these essential therapies, including albumin and immunoglobulins, are constrained globally, particularly in healthcare systems with limited budgets. This directly limits the broader market penetration for these vital products.

The extensive infrastructure and specialized operational requirements inherent in the supply chain contribute to these high costs. For instance, according to the Georgetown Blood and Plasma Research Group, in 2025, the United States alone housed 1,247 plasma collection centers. The maintenance and staffing of such a large network, coupled with the intricate, energy-intensive, and highly regulated fractionation procedures, incur substantial operational expenditures. These financial burdens are passed on to the final product, resulting in high treatment costs that restrict wider patient access and hinder market expansion across various international regions.

Key Market Trends

The emergence of novel and specialized plasma-derived therapies represents a significant trend, expanding the utility of plasma fractionation beyond traditional products. This involves developing new protein fractions or modifying existing therapies to address a broader spectrum of complex medical conditions with enhanced efficacy or targeted action. Companies are increasing research and development investments to diversify their product portfolios and serve unmet medical needs. For instance, according to Octapharma's 2025 Annual Report, published in February 2026, the company invested €117 million in research and development, highlighting the industry's commitment to fostering innovation and bringing forth next-generation plasma-derived treatments. This focus creates new therapeutic categories and extends market reach.

The adoption of advanced purification and separation technologies constitutes another critical trend, revolutionizing the efficiency and safety of the plasma fractionation process. These technological advancements enable higher yields of plasma proteins, improve product purity, and can reduce manufacturing costs. Such innovations are crucial for enhancing production scalability and ensuring the availability of high-quality, safe plasma-derived medicinal products. For example, according to Fierce Pharma, March 2026, CSL initiated a $1.5 billion expansion at its Kankakee facility, integrating its Horizon 2 production process, a yield-enhancing technology designed to produce greater quantities of immunoglobulin from the same amount of plasma. This investment underscores the industry’s drive towards process optimization and technological superiority.

Segmental Insights

In the global plasma fractionation market, the albumin segment is emerging as a rapidly expanding area, driven by its versatile therapeutic applications across numerous medical conditions. The increasing use of albumin in critical care, liver diseases, and as a drug carrier is fueling demand due to its essential role in maintaining oncotic pressure and transporting substances. Furthermore, advancements in biotechnological production methods have improved availability and cost-efficiency, contributing to its expanded adoption. Stringent regulatory oversight from bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) ensures product quality and safety, thereby fostering healthcare provider and patient confidence and supporting market growth.

Regional Insights

North America leads the global plasma fractionation market due to its advanced healthcare infrastructure and robust plasma collection networks. The region benefits from the strong presence of major biopharmaceutical companies that extensively invest in research and development for novel plasma-derived therapies. High demand for these therapies, driven by a significant prevalence of chronic and rare diseases, further propels market expansion. Moreover, a supportive regulatory environment, spearheaded by institutions like the U.S. Food and Drug Administration, ensures stringent quality and safety standards for plasma products, contributing to market confidence and growth.

Recent Developments

• In March 2026, CSL Behring initiated a significant $1.5 billion expansion of its manufacturing facility located in Kankakee, Illinois, directly impacting the Global Plasma Fractionation Market. This project is designed to substantially increase the company's production capabilities for plasma-derived therapies, particularly focusing on immunoglobulin treatments. The expansion is expected to generate a considerable number of new skilled pharmaceutical jobs. By incorporating advanced manufacturing processes, CSL Behring aims to enhance the yield of immunoglobulin from collected plasma, further securing the supply of these critical treatments for patients worldwide.
• In February 2026, Indonesia neared completion of its inaugural plasma fractionation facility in Karawang, West Java, a pivotal development for the global market. This plant resulted from a significant public-private partnership between the Indonesia Investment Authority (INA) and South Korean SK Plasma, aiming for commercial operations to commence in 2026. The facility, poised to become the largest of its kind in Southeast Asia, will have an annual processing capacity of approximately 600,000 liters of plasma. This initiative is set to significantly reduce Indonesia's dependence on imported plasma-derived medicinal products.
• In September 2025, Takeda Pharmaceuticals reaffirmed its commitment to enhancing its global plasma-derived therapies manufacturing network. The company provided an update on the expansion of its facility in Juso, Osaka, Japan, a project crucial for increasing capacity within the Global Plasma Fractionation Market. Takeda announced an upward revision of the total investment to 153 billion yen for this expansion, with the construction phase initiated in fiscal year 2025. The completion is targeted for fiscal year 2029, though the company indicated a reevaluation of the project's scope and timeline due to increased construction costs and ongoing labor shortages in the region.
• In July 2025, Grifols announced a substantial investment of EUR 160 million toward establishing a new manufacturing facility in Lliçà de Vall, Barcelona, Spain. This strategic initiative aimed to double the company's plasma fractionation capacity across Europe, thereby strengthening its ability to supply essential plasma-derived medicines to patients. The construction commenced in 2025, with projected operations beginning in 2030. This new plant, spanning over 80,000 square meters, will be integrated into a larger biotechnology hub, underscoring Grifols' commitment to meeting the increasing demand for plasma-derived therapies.

Key Market Players

• Grifols S.A.
• Octapharma AG
• Intas Pharmaceuticals Ltd
• LFB S.A.
• Takeda Pharmaceutical Company Limited
• CSL Limited
• Biotest AG
• Kedrion S.p.A
• Bio Products Laboratory Ltd.
• Bharat Serums and Vaccines Limited

By Product	By Application	By Region
Albumin Immunoglobulins Coagulation Factors Protease Inhibitors Others	Neurology Hematology Oncology Immunology Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Plasma Fractionation Market, By Product:

• Albumin
• Immunoglobulins
• Coagulation Factors
• Protease Inhibitors
• Others

• Plasma Fractionation Market, By Application:

• Neurology
• Hematology
• Oncology
• Immunology
• Others

• Plasma Fractionation Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE